Survodutide delivers 13.1% weight loss in Phase III trial for obesity and type 2 diabetes

Survodutide achieved a 13.1% mean body weight loss over 76 weeks in a Phase III trial for obesity and type 2 diabetes, meeting key endpoints including weight reduction and improved glycemic control. The drug, a dual glucagon/GLP-1 receptor agonist, adds a metabolic action that may differentiate it from existing treatments, with Boehringer Ingelheim preparing a regulatory submission.

This Wire brief sits within Fusion42's coverage of Drug Discovery and Biotech.